Home › Glucose Intolerance › NCT05051436
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Who can join
Ages 35 to 65 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Hemoglobin A1C between 5.7 and 6.4 * Body mass index between 27 and 45 Exclusion Criteria: * Diabetes * Chronic use of any antidiabetic medications * Any unstable medical condition * Use of steroids or daily use of NSAIDS * History of chronic inflammatory conditions * Use of anticoagulants * Contraindications to the use of mirabegron or tadalafil * Any condition deemed risky by the study physician
About the study
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
What is being tested
- Mirabegron 50 MG (drug)
- Tadalafil 10 MG (drug)
- Placebo (drug)
Sponsor: Philip Kern · Participants: 96 · Started: Dec 13, 2021
Contact the study team
- Zach Leicht · Phone: 859-218-1397
- Philip Kern, M.D. · Phone: 859-218-1394
Official record on ClinicalTrials.gov — NCT05051436
Locations in the U.S.
| Kentucky | University of Kentucky, Lexington |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.